Supported by research led by our Dr. Funda Meric-Bernstam, U.S. FDA granted accelerated approval today to fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2 positive solid tumors who have received prior systemic treatment and have no

🔥 U.S. FDA grants accelerated approval to the AGNOSTIC 🎯 use of TDxd for #HER2 IHC3+ M+ solid tumors based on DESTINY-PanTumor02/Lung01/CRC02 data w/ ORR of up to 52%.9% and long DOR.

When the 3 of us have the same clinic day — it’s group photo update time! 📸 Carlos Torrado Mohamed A Gouda MD Anderson Cancer Center

Our editorial addressing the challenges & opportunities of the Phase I Clinical Trials 🧬 scenario in Latin America is out! Mirella Nardo, MD SBOC 🇧🇷 JIPO Editors Aung Naing ⁦MD Anderson Cancer Center⁩ meridian.allenpress.com/innovationsjou…

Peer reviewing for high-quality journals is a great opportunity to improve your writing skills. Also, if reviewing for #JIPO you will be in touch with the newest evidence in the field of #immunotherapy & #PrecisionOncology ! Apply today👇

Aung Naing At JIPO Editors, we consider ourselves fortunate to have @AnaingMD as our Editor-in-Chief, alongside our brilliant editorial board members Jyoti Bajpai Sewanti Limaye 🇮🇳🇺🇸 Sanam Loghavi, MD صنم لغوی 🔬🧬 Herbert Loong Christophe Massard Christian Rolfo Naveen Pemmaraju, MD Gil Morgan, MD Shannon Westin, MD, MPH, FASCO

ASCO ASCOTECAG ⬇️ Quick & easy important survey re: role of ASCO in clinical research, specifically addressing research priorities and implementation & barriers.

Although brutally real, a beautiful essay from Bishal Gyawali in The Lancet Oncology. We need to perform better for #PancreaticCancer patients!

51 years in the making till #GU24 . OS benefit in adjuvant Renal Cancer is finally here. #KYN564

Ph Ib/II study evaluating colony-stimulating factor 1 (CSF-1) blockage + anti-PD1. One PDAC pt w/ immune-related SD for 26 mo. Should it be pursued on late ph for #pancreatic ? Check out on JIPO Editors ! Jibran Ahmed Bettzy Stephen Evan Kwiatkowski Chinenye Lynette Ejezie Dr. Shubham Pant

Excellent insights on ctDNA 🧬 dynamic changes, its correlation with treatment response and LB-RECIST feasibility — a must-read perspective paper from Mohamed A Gouda & colleagues at Annals of Oncology ESMO - Eur. Oncology

The ASCO #TECAG is hard at work, getting ready for #ASCO2024 !!
📢If you're interested in joining this 🔥phenomenal group of oncologists, consider applying! volunteer.asco.org/application
➡️Deadline: January 31, 2024 for the 2024-2025 cohort.⏰

Fernando Diaz, MD Ana I. Velázquez Mañana, MD MSc (she/her/ella) Ramy Sedhom, MD

A rare case of primary carcinosarcoma of the peritoneum after risk-reducing BSO in a BRCA2 pathogenic variant carrier & BC survivor. 🧬 Thank you ⁦⁦Daniele Assad Suzuki⁩ & team ⁦Sírio-Libanês⁩ #casereport #oncology #breastcancer #BRCA karger.com/cro/article/17…

It was a pleasure to have contributed to #JIPO as an editorial fellow under the guidance of the great Aung Naing over the past year. I learn more about editorial process, #immunotherapy & #PrecisionOncology every day w/ the JIPO Editors team. Looking forward to 2024 publications!

Congrats Clarissa Mathias !! Your commitment to ASCO is an example for 🇧🇷 young oncologists ASCOTECAG Cissa Mathias

Had so much fun discussing and doing the ESMO2023 NSCLC review with Camila Bragança Xavier Diogo Silva Thank you JIPO Editors !